Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Respiratory syncytial virus RSV is a common virus affecting children, especially young babies, premature infants, and those with heart or lung problems. It is a leading cause of hospitalization for children under 5 years old globally, with many severe cases and deaths occurring in low- and middle-income countries. This research evaluates the safety of an RSV vaccine called ABRYSVO given to pregnant women and how well it protects their infants from severe RSV infections during the first six months of life, particularly in African and lower-middle income countries where data is limited. Pregnant women will receive either the ABRYSVO vaccine or a placebo in a randomized, double-blind trial. The vaccine contains stabilized RSV prefusion F antigens from virus subgroups A and B. The study will enroll pregnant women at the approved gestational age for vaccination, with participants randomly assigned to receive either the vaccine or placebo in equal numbers. The trial will monitor the safety of the vaccine in mothers and infants and measure how well the vaccine prevents severe RSV lower respiratory tract infections in babies up to 180 days old. Participants will attend antenatal clinics and provide informed consent for themselves and their infants. Researchers will follow the women through pregnancy and delivery, recording any preterm births and birth weights. Infants will be monitored for RSV infections confirmed by laboratory tests, and hospitalizations due to RSV will be tracked up to six months of age. Safety assessments include monitoring adverse events in mothers and babies, with follow-up visits and telephone contacts to ensure comprehensive data collection throughout the trial period.
Actively Recruiting
Researchers are evaluating etavopivat, a new oral medicine being developed for blood disorders such as sickle cell disease and thalassaemia. These inherited conditions affect hemoglobin, the protein responsible for carrying oxygen in the body. This long-term study aims to assess the safety and effectiveness of etavopivat treatment over a period of up to 264 weeks, or until the drug is approved in the participants country. Participants will receive one of several oral doses of etavopivat, with dosing adjusted by age those 12 years and older will receive Etavopivat A or C, while children younger than 12 years will receive Etavopivat B. The study involves multiple groups including adults, adolescents, and children with different types of sickle cell disease or thalassaemia. All participants have completed a prior etavopivat treatment study and are continuing treatment in this rollover study. During the study, participants will be regularly monitored for treatment-related side effects and clinical benefits. Researchers will track adverse events, blood crisis rates, hemoglobin levels, hospitalizations, and blood transfusion needs. The study includes long-term safety and efficacy assessments conducted over several years, with monitoring continuing until study completion or drug approval. Participants health and treatment responses will be carefully followed throughout this extended period.
Actively Recruiting
Researchers are evaluating etavopivat in adolescents and adults with sickle cell disease to see if it can reduce vaso-occlusive crises painful blockages in blood vessels and protect organs from damage. This phase 3 study will also assess whether etavopivat improves exercise tolerance and reduces fatigue compared to a placebo. The trial is randomized, double-blind, and placebo-controlled to ensure unbiased results on the medications effects. Participants will be randomly assigned to receive either oral etavopivat or a matching placebo. The study treatment is taken by mouth, and participants will be followed closely for about 2 years. This includes monitoring during the treatment period and ongoing assessments to evaluate the drugs impact on sickle cell disease symptoms and related health measures. Throughout the study, participants will undergo evaluations such as blood tests to measure hemoglobin and other markers, 6-minute walking tests to assess exercise capacity, and fatigue questionnaires. Researchers will track the number of vaso-occlusive crises requiring medical contact over 52 weeks as the primary outcome. Safety and efficacy will be monitored regularly, with follow-up continuing until the study ends approximately 4 years after enrollment begins.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of a combination of anti-malarial drugs in children aged 2 to under 12 years with uncomplicated Plasmodium falciparum malaria. This phase 2 platform study compares a single oral dose of up to three anti-malarial agents given together to the standard treatment known as Coartem. The study aims to better understand how these treatments work and their safety profiles in this young population. Participants are randomly assigned to one of two groups one receiving an oral combination of KLU156 with KAE609 alongside a light meal, and the other receiving the standard of care, Artemether plus lumefantrine, given orally according to the usual guidelines. This open-label, two-arm study monitors each treatment groups response to therapy. Throughout the study, participants undergo evaluations including parasite clearance times and blood tests to measure drug levels over the first week, with the main outcome assessed on day 29 using PCR to confirm clinical and parasitological response. Safety and tolerability are also closely monitored, and the total duration of participation extends up to 29 days after treatment initiation to assess treatment outcomes comprehensively.
Actively Recruiting
Researchers are evaluating how well different anti-malarial drugs work and how safe they are for treating uncomplicated Plasmodium falciparum malaria in adults, adolescents, and children. This study focuses on the parasite-killing effects and potential cure rates of these drugs when given alone or combined with others. It also looks at how the drugs are processed by the body to help decide doses for future studies. Participants will receive one of several treatments, including varying doses of the oral drug INE963, combinations of oral KAE609 Cipargamin with INE963 or KLU156, or the standard of care drug Coartem. The study has multiple parts with patients allocated randomly to different treatment groups. Dosing levels and combinations are tested to compare how effectively they clear the malaria parasite. During the study, participants will have their parasite levels monitored up to 7 days and clinical response assessed by day 29. Blood samples will be taken by day 22 to study drug levels and how the body absorbs and clears the medicines. Safety is monitored through reports of side effects until day 43. The total participation lasts through these assessments to understand treatment impact and tolerability.
Actively Recruiting
Healthy Volunteer
Access to quality antenatal and postnatal care is crucial to reducing pregnancy-related health problems and supporting positive birth experiences. Despite World Health Organization recommendations for eight antenatal visits, coverage and quality of care remain inconsistent, especially in vulnerable populations and resource-poor regions. This study aims to evaluate pregnancy risk factors and their links to adverse outcomes like stillbirth, neonatal mortality, and maternal morbidity in low- and middle-income countries to help improve maternal and newborn health. The study follows a large open cohort design to gather harmonized data on maternal and newborn health from multiple centers. It observes pregnant women from early pregnancy under 20 weeks gestation through delivery and postpartum periods, focusing on risk factors and outcomes without providing specific treatments. The research collects information on maternal mortality, severe maternal outcomes, anemia, stillbirth, neonatal mortality, preterm birth, low birth weight, and small-for-gestational-age infants. Participants will be monitored from pregnancy identification around 10-20 weeks gestation through delivery and up to one year postpartum. Assessments include maternal and infant health outcomes measured at various timepoints such as delivery, 42 days postpartum, and up to 12 months after birth. The study tracks important maternal and infant conditions, including infections, hypertension, diabetes, depression, and infant growth, aiming to better understand risks and inform future care strategies.
Actively Recruiting
Researchers are evaluating the RTS,SAS01 malaria vaccine through case-control studies embedded within the Malaria Vaccine Pilot Evaluation MVPE conducted in Ghana, Malawi, and Kenya. This observational study aims to assess the vaccines safety with focus on cerebral malaria, meningitis, and severe malaria, as well as its impact on all-cause mortality among children aged 6 months to 59 months. The study also supports the use of case-control methods in immunization and malaria control programs. The study involves two main case-control components clinical outcomes and mortality outcomes. For clinical outcomes, children living in MVPE areas who meet case or control definitions based on hospital surveillance are recruited, with each case matched to four controls. The mortality component recruits children who died from any cause excluding accidents or trauma and matches them with four live controls. Data collection includes administering questionnaires to caregivers at their homes and gathering information from hospital and community surveillance systems. Participants will be involved through consented data collection via questionnaires and surveillance records. Data on meningitis, severe malaria, cerebral malaria, and mortality by gender are collected and analyzed. Controls are recruited by canvassing households near cases to match age and location. The study spans 45 months, with ongoing monitoring of outcomes including hospital admissions and deaths. Findings will support vaccine safety and effectiveness assessments and inform policy decisions.